Skin radiosensitization studies using combined cis-dichlorodiammineplatinum (II) and radiation

Douple, Evan B.; Eaton, Lucia J.; Tulloh, Marchant

doi:10.1016/0360-3016(79)90675-8

Cited by 62 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that CDDP increased irradiation i njury. 21 We used jejunal crypt cell assay to investigate whether our NLE-CDDP would increase toxicity. When combined with irradiation, NLE-CDDP yielded lower survival of crypt cells than did irradiation alone, with SER of 1.15, whereas CDDP also sensitized irradiation injury of jejunal crypt cell with SER of 1.19.…”

Section: Discussionmentioning

confidence: 99%

In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer

Zhang¹,

Yang²,

Gu³

et al. 2011

IJN

View full text Add to dashboard Cite

Objective: To investigate the in vitro and in vivo radiosensitization effect of an institutionally designed nanoliposome encapsulated cisplatin (NLE-CDDP). Materials and methods: NLE-CDDP was developed by our institute. In vitro radiosensitization of NLE-CDDP was evaluated by colony forming assay in A549 cells. In vivo radiosensitization was studied with tumor growth delay (TGD) in Lewis lung carcinoma. The radiosensitization for normal tissue was investigated by jejunal crypt survival. The radiosensitization studies were carried out with a 72 h interval between drug administration and irradiation. The mice were treated with 6 mg/kg of NLE-CDDP or CDDP followed by single doses of 2 Gy, 6 Gy, 16 Gy, and 28 Gy. Sensitization enhancement ratio (SER) was calculated by D 0 s of cell survival curves for A549 cells, doses needed to yield TGD of 20 days in Lewis lung carcinoma, or D 0 s of survival curves in crypt cells in radiation alone and radiation plus drug groups. Results: Our NLE-CDDP could inhibit A549 cells in vitro with half maximal inhibitory concentration of 1.12 μg/mL, and its toxicity was 2.35 times that observed in CDDP. For in vitro studies of A549 cells, SERs of NLE-CDDP and CDDP were 1.40 and 1.14, respectively, when combined with irradiation. For in vivo studies of Lewis lung carcinoma, the strongest radiosensitization was found in the 72 h interval between NLE-CDDP and irradiation. When given 72 h prior to irradiation, NLE-CDDP yielded higher radiosensitization than CDDP (SER of 4.92 vs 3.21) and slightly increased injury in jejunal crypt cells (SER of 1.15 vs 1.19). Therefore, NLE-CDDP resulted in a higher TGF than did CDDP (4.28 vs 2.70) when SERs were compared between experiments in vivo and in jejunal crypt cell studies. Conclusions: Our NLE-CDDP was demonstrated to have radiosensitization with TGF of 4.28 when administrated 72 h prior to irradiation.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer

Zhang¹,

Yang²,

Gu³

et al. 2011

IJN

View full text Add to dashboard Cite

show abstract

“…The low toxicity of this treatment regimen wae evident, as only two patients were unable to complete the course of preoperative therapy. Chemotherapy and radiotherapy schedules did not have to be altered in any of the remaining 16 patients, Douple et al 32 reported cutaneous toxicity in experimental Cis-DDP sensitized irradiation when the Cis-DDP dosage ex-162 Cis-DDP/Radiotherapy in Head and Neck Cancer ceeded 2.5 mgkg. The daily dosage of Cis-DDP in this study was well below that level, which may account for the minimal cutaneous toxicity observed.…”

Section: Discussionmentioning

confidence: 95%

Preoperative simultaneously administered cis‐platinum plus radiation therapy for advanced squamous cell carcinoma of the head and neck

et al. 1986

View full text Add to dashboard Cite

Synchronously administered cis-platinum (cis-DDP) and radiation therapy have been used to treat unresectable squamous cell carcinomas of the head and neck. The purpose of this study was to evaluate the efficacy and tolerance of preoperative adjuvant cis-DDP plus radiation therapy in operable stage III and IV head and neck cancers. Radiation therapy (4,500 rad) was delivered in 180-rad daily fractions. Cis-DDP (20 mg/M2) was given before radiotherapy on days 1-4 and 21-24. Eighteen patients began therapy; 16 completed the combined regimen. Toxicity included stomatitis and WBC below 2,500/mm3. One patient died from therapy of a cerebrovascular accident. Sixteen patients (89%) achieved a complete or partial response to therapy. Complete responses were observed in 13 of 18 primary tumors (72%), and in all three patients with cervical lymphadenopathy. Complete responses were noted for lesions of the nasopharynx, oral cavity, pharynx, hypopharynx, and larynx, for all histologic grades of squamous cell carcinoma. Twelve patients underwent curative surgery. Site-related morbidity occurred in two patients (15%) and a third patient developed postoperative pneumonia. Five of 10 resected primary tumors with preoperative complete responses were pathologically negative for tumor. Concurrent bolus cis-DDP and radiation therapy are well-tolerated and result in impressive tumor reduction. Morbidity after subsequent curative surgery is low, and histologic complete responses are frequent.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

“…Some investigators, however, did show a moderate increase of skin reactions in mouse foot (von der Maase, 1984b) as well as in the rat foot (Douple et al, 1979). A phase I/II clinical study combining radiotherapy and daily low dose cis-DDP for treatment of locally advanced cancers showed no clear increase of the oral mucosal reactions or skin lesions (Keizer et al, 1984).…”

Section: Discussionmentioning

confidence: 99%

Combinations of single doses and fractionated treatments of cis-dichlorodiammineplatinum (II) and irradiation: Effect on mouse lip mucosa

Landuyt¹,

Ang²,

Schueren³

1987

Br J Cancer

View full text Add to dashboard Cite

Tolerance of the lip mucosa of NMRI mice to single and fractionated irradiation combined with cis-diamminedichloroplatinum (II) (cis-DDP) was investigated. For the various combination schedules total drug doses varying from 6 mg kg-1 to 13 mg kg-1 were injected i.p. It was found that cis-DDP did not alter the radiation sensitivity of this tissue at any of the time intervals tested (ranging from 24 h before to 72 h after single dose irradiations). When 5 daily drug injections were given concomitantly with 5 daily radiation treatments, a slight reduction of the lip mucosal reactions occurred, possibly due to partial synchronisation during treatment. No effect was seen when a single injection of cis-DDP preceded two irradiations given with increasing intervals up to 4 h. Both these combined fractionated treatment data suggest no inhibitory effect on repair of sublethal radiation damage. When repeated daily injections of cis-DDP were given in between 2 radiation doses separated by 10 days, no interference with repopulation could be detected. The present study also demonstrated an increase in systemic drug toxicity when cis-DDP was combined with irradiation, compared with that seen with either agent alone.

show abstract

Skin radiosensitization studies using combined cis-dichlorodiammineplatinum (II) and radiation

Cited by 62 publications

References 3 publications

In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer

In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer

Preoperative simultaneously administered cis‐platinum plus radiation therapy for advanced squamous cell carcinoma of the head and neck

Combinations of single doses and fractionated treatments of cis-dichlorodiammineplatinum (II) and irradiation: Effect on mouse lip mucosa

Contact Info

Product

Resources

About